Effects of zuranolone: A Synthesis of Findings from 16 Studies

  1. Home
  2. Effects of zuranolone
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of zuranolone: A Synthesis of Findings from 16 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of zuranolone: A Synthesis of Findings from 16 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Several studies have shown that zuranolone has rapid antidepressant effects in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). 15 , 14 , 13 After 14 days of treatment, zuranolone significantly reduced Hamilton Rating Scale for Depression (HAM-D) scores in patients with PPD or MDD compared to placebo. 15 Additionally, a higher percentage of patients with PPD or MDD achieved HAM-D response and remission with zuranolone treatment compared to placebo. 15 These effects are believed to be due to zuranolone's ability to enhance inhibitory GABAergic signaling by increasing synaptic and extrasynaptic GABAA receptor activity and regulating GABAA receptor expression. 14

Zuranolone has been approved by the FDA for the treatment of postpartum depression and is showing efficacy in major depressive disorder. 6 , 14 However, further research is needed to determine the durability of this treatment approach and its effects on domain-specific outcomes, as well as its application in other diagnostic entities such as bipolar depression. 14

Benefits and Risks

Benefit Summary

Multiple studies have shown that zuranolone has rapid antidepressant effects in the treatment of MDD and PPD. 15 , 14 , 13 After 14 days of treatment, zuranolone significantly reduced HAM-D scores in patients with PPD or MDD compared to placebo. 15 Additionally, a higher percentage of patients with PPD or MDD achieved HAM-D response and remission with zuranolone treatment compared to placebo. 15

Risk Summary

Zuranolone has been associated with side effects such as somnolence, dizziness, and sedation. 15 While serious adverse events have not been reported, further research is needed to fully understand the potential risks. 14

Comparison Between Studies

Similarities Between Studies

Multiple studies have shown that zuranolone has rapid antidepressant effects in the treatment of MDD and PPD. 15 , 14 , 13 Additionally, studies have demonstrated that zuranolone acts as a positive allosteric modulator of GABAA receptors, enhancing GABAergic signaling. 14

Differences Between Studies

There are differences in the effectiveness, frequency, and severity of side effects reported in different studies. 15 , 14 These differences may be influenced by variations in study design, participant characteristics, and other factors.

Consistency and Contradictions in Results

Multiple studies have consistently demonstrated that zuranolone has rapid antidepressant effects in the treatment of MDD and PPD. 15 , 14 , 13 However, there is variability in the effectiveness, frequency, and severity of side effects across studies, highlighting the need for further research.

Implications for Real-Life Applications

Zuranolone holds promise as a treatment for MDD and PPD, but it's important to be aware of the potential for side effects. 15 Furthermore, research on long-term efficacy, effects on domain-specific outcomes, and the impact on various patient groups is still ongoing. 14

Limitations of Current Research

Research on zuranolone is still relatively limited, and further investigation is warranted. 15 , 14 Specifically, more research is needed on long-term efficacy, effects on domain-specific outcomes, the impact on various patient groups, and the combined effects of zuranolone with other treatment methods.

Future Research Directions

Further research is necessary to investigate the long-term efficacy of zuranolone, its impact on domain-specific outcomes, its effects on various patient groups, and its combined effects with other treatment methods. 14

Conclusion

Zuranolone is a promising drug that has shown rapid antidepressant effects in the treatment of MDD and PPD. 15 , 14 , 13 However, it's essential to be mindful of the potential for side effects. 15 Further research is crucial to gain a more comprehensive understanding of zuranolone's effectiveness and safety.

Literature analysis of 16 papers
Positive Content
15
Neutral Content
1
Negative Content
0
Article Type
4
0
0
11
16
1.

Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers.

Author: DixonR M, MeireH B, EvansD H, WattH, OnN, PosnerJ, RolanP E

Migraine treatment
Vasoconstriction

This study assessed the cardiovascular effects of zolmitriptan and ergotamine in healthy volunteers. Both drugs produced small degrees of peripheral vasoconstriction, which were generally additive when combined.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

2.

The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90).

Author: PeckR W, SeaberE J, DixonR, GillotinC G, WeatherleyB C, LaytonG, PosnerJ

Cardiovascular effects

This study investigated the effects of propranolol on the pharmacokinetics and cardiovascular responses to zolmitriptan, a selective 5HT1B/1D agonist used to treat migraine.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

3.

Effects of the antimigraine compound zolmitriptan ('Zomig') on psychomotor performance alone and in combination with diazepam in healthy volunteers.

Author: DixonR, HughesA M, NairnK, SellersM, KempJ V, YatesR A

Zolmitriptan 2.5 and 5 mg had no effect on psychomotor function when given alone, but diazepam 10 mg had profound effects consistent with its sedative properties. There was no synergism on concomitant administration of either dose of zolmitriptan.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

4.

Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder.

Author: SuthoffEllison, KosinskiMark, ArnaudAlix, HodgkinsPaul, Gunduz-BruceHandan, LasserRobert, SilberChristopher, SankohAbdul J, LiHaihong, WerneburgBrian, JonasJeffrey, DohertyJames, KanesStephen J, BonthapallyVijayveer

Improved HRQoL

Zuranolone was associated with rapid and significant improvements in health-related quality of life compared to placebo in patients with major depressive disorder.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Clinical specificity profile for novel rapid acting antidepressant drugs.

Author: ScalaMauro, FanelliGiuseppe, De RonchiDiana, SerrettiAlessandro, FabbriChiara

Improved symptom targeting
Rapid antidepressant action
Tolerable profile

This review discusses the clinical specificity profile of novel antidepressants, focusing on their potential to address specific symptoms such as anhedonia and suicidal ideation.

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Zuranolone: The First FDA-Approved Oral Treatment Option for Postpartum Depression.

Author: BarnesKylie N, VoglClaire M, NelsonLeigh Anne

Oral administration
Rapid onset of effect

Zuranolone, an oral medication, is a rapid-acting treatment for postpartum depression (PPD) and is effective in improving depressive symptoms.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

7.

Novel antidepressant drugs: Beyond monoamine targets.

Author: GondaXenia, DomePeter, NeillJoanna C, TaraziFrank I

Improved efficacy of antidepressants
Reduced side effects

Antidepressants have been largely focused on targeting monoamine neurotransmitters but have limited efficacy and side effects. Novel antidepressants are being developed that target other pathways, including glutamatergic and GABAergic pathways, to improve efficacy, safety, and tolerability. Psychedelic drugs like psilocybin, Ayahuasca, 5-MeO-DMT, and LSD are also being explored as potential treatments for depression.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Current pharmacotherapy approaches and novel GABAergic antidepressant development in postpartum depression.

Author: CarliniSara V, OsborneLauren M, DeligiannidisKristina M

Reduced symptoms
Limited efficacy

Postpartum depression is a common and serious condition. This review discusses current and emerging treatments for postpartum depression, including pharmacotherapy, hormonal therapy, and allopregnanolone analogues.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

10.

New Pharmacologic Approaches to the Treatment of Bipolar Depression.

Author: KeramatianKamyar, ChakrabartyTrisha, DuBoisAnais, SarafGayatri, YathamLakshmi N

BD depression treatment

This review examines emerging and potential treatments for depression in patients with bipolar disorder.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

11.

Translocator protein (18kDa) TSPO: a new diagnostic or therapeutic target for stress-related disorders?

Author: RupprechtRainer, WetzelChristian H, DorostkarMario, HermsJochen, AlbertNathalie L, SchwarzbachJens, SchumacherMichael, NeumannInga D

Antidepressant effects
Anxiolytic effects
Stress-related disorder treatment

This article discusses the challenges of treating stress-related disorders like depression and explores the potential of TSPO (translocator protein 18k Da) as a target for new treatments. TSPO ligands have shown promise in preclinical studies, suggesting potential for developing novel antidepressant and anxiolytic therapies.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development.

Author: FriederAriela, FershMadeleine, HainlineRachel, DeligiannidisKristina M

Postpartum depression treatment

Brexanolone and SAGE-217, drugs being developed for postpartum depression, have shown promise in reducing depressive symptoms.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

14.

Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder.

Author: MeshkatShakila, TeopizKayla M, Di VincenzoJoshua D, BaileyJulia B, RosenblatJoshua D, HoRoger C, RheeTaeho Greg, CebanFelicia, KwanAngela T H, CaoBing, McIntyreRoger S

Acceptable adverse events
Clinically meaningful effects
Rapid antidepressant effects

Zuranolone is a novel oral neuroactive steroid that has shown promising results in treating major depressive disorder (MDD). In seven studies involving 1662 participants, Zuranolone demonstrated rapid and clinically significant antidepressant effects, with an acceptable safety profile and a low rate of serious adverse events. It is believed that Zuranolone's efficacy stems from its ability to enhance inhibitory GABAergic signaling.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

15.

Efficacy and safety of zuranolone for the treatment of depression: A systematic review and meta-analysis.

Author: LiZejun, WuQiuxia, PengPu, WuMin, LiuShouhuan, LiuTieqiao

MDD treatment
PPD treatment
Rapid antidepressant effects
Dizziness
Sedation
Somnolence

Zuranolone, a neuroactive steroid, showed rapid antidepressant effects in both major depressive disorder (MDD) and postpartum depression (PPD) in clinical trials. While it exhibited a favorable safety and tolerability profile, further research is needed to evaluate its long-term efficacy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.